This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. PLX, IKT, ZIVO, IZTC, CRTX, CVM, JATT, FNCH, CLDI, and ALVRShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Cortexyme (CRTX), CEL-SCI (CVM), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), Calidi Biotherapeutics (CLDI), and AlloVir (ALVR). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Its Competitors Protalix BioTherapeutics Inhibikase Therapeutics ZIVO Bioscience Invizyne Technologies Cortexyme CEL-SCI JATT Acquisition Finch Therapeutics Group Calidi Biotherapeutics AlloVir Proteon Therapeutics (NASDAQ:PRTO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of PRTO or PLX? 23.0% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, PRTO or PLX? Proteon Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Does the media prefer PRTO or PLX? In the previous week, Protalix BioTherapeutics had 9 more articles in the media than Proteon Therapeutics. MarketBeat recorded 9 mentions for Protalix BioTherapeutics and 0 mentions for Proteon Therapeutics. Protalix BioTherapeutics' average media sentiment score of 0.45 beat Proteon Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Proteon Therapeutics Neutral Protalix BioTherapeutics Neutral Do analysts recommend PRTO or PLX? Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 803.61%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRTO or PLX more profitable? Proteon Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Proteon Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteon TherapeuticsN/A N/A -118.68% Protalix BioTherapeutics -21.03%-30.89%-11.74% Which has stronger valuation and earnings, PRTO or PLX? Protalix BioTherapeutics has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteon TherapeuticsN/AN/A-$20.73M-$1.15-2.70Protalix BioTherapeutics$61.95M2.14$8.31M$0.0723.71 SummaryProtalix BioTherapeutics beats Proteon Therapeutics on 9 of the 15 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.76M$283.21M$5.83B$9.73BDividend YieldN/AN/A3.84%4.09%P/E Ratio-2.70N/A31.1625.99Price / SalesN/A479.90474.86122.97Price / CashN/A22.4437.1558.38Price / Book-51.6710.449.116.38Net Income-$20.73M-$115.81M$3.26B$265.56M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.10+2.3%N/A+37.7%$68.76MN/A-2.7017PLXProtalix BioTherapeutics3.0621 of 5 stars$1.64+1.9%$15.00+814.6%+62.9%$130.56M$59.76M-12.62200News CoverageAnalyst RevisionIKTInhibikase Therapeutics1.7616 of 5 stars$1.75+15.9%$6.50+271.4%+15.9%$130.10MN/A-0.666ZIVOZIVO Bioscience0.2804 of 5 stars$18.01+11.1%N/A+102.4%$68.74M$15.85K-3.6910News CoverageGap UpHigh Trading VolumeIZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029News CoverageGap DownCRTXCortexymeN/A$1.60-3.0%N/A+154.7%$58.79MN/A-0.5455CVMCEL-SCI1.438 of 5 stars$7.63+8.5%N/A-73.1%$52.51MN/A-15.9043JATTJATT AcquisitionN/A$1.41-0.7%N/A-50.7%$24.32MN/A0.003Gap UpHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.25+0.1%N/A+22.1%$19.67MN/A-1.39190CLDICalidi Biotherapeutics0.7917 of 5 stars$5.29+5.0%N/A-90.6%$16.01MN/A0.0038News CoverageALVRAlloVirN/A$2.67-1.5%N/A-85.5%$13.47MN/A-0.13110 Related Companies and Tools Related Companies Protalix BioTherapeutics Alternatives Inhibikase Therapeutics Alternatives ZIVO Bioscience Alternatives Invizyne Technologies Alternatives Cortexyme Alternatives CEL-SCI Alternatives JATT Acquisition Alternatives Finch Therapeutics Group Alternatives Calidi Biotherapeutics Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access